Celcuity (CELC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Voting matters and shareholder proposals
Election of eight directors is proposed, with all nominees recommended for approval by the board.
Ratification of Boulay PLLP as the independent registered public accounting firm for the year ending December 31, 2026 is up for vote.
Advisory approval of named executive officer compensation is included as a voting item.
Approval of the 2026 Stock Incentive Plan and the Amended and Restated Employee Stock Purchase Plan are proposed.
Proxies may vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Eight director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is scheduled, allowing shareholders to express approval or disapproval.
A new 2026 Stock Incentive Plan and an amended Employee Stock Purchase Plan are proposed for approval.
Latest events from Celcuity
- Shareholders will vote on directors, auditor, executive pay, and new equity plans at the 2026 meeting.CELC
Proxy filing2 Apr 2026 - FDA Priority Review, strong trial data, and $441.5M cash position support 2026 launch.CELC
Q4 202525 Mar 2026 - Gedatolisib demonstrates leading efficacy in breast cancer, with launch and global expansion underway.CELC
Leerink Global Healthcare Conference 202610 Mar 2026 - Gedatolisib nears launch with strong trial data, regulatory momentum, and $10B+ peak potential.CELC
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential.CELC
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026 - Phase III breast cancer trial for gedatolisib on track, with strong safety and multi-billion market potential.CELC
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 saw robust clinical progress, $129M raised, and $283.1M cash reserves for future growth.CELC
Q2 20241 Feb 2026 - Gedatolisib set new benchmarks in efficacy and safety for advanced breast cancer.CELC
Status Update14 Jan 2026 - Phase III enrollment milestones reached; $264M cash supports pivotal 2025 data and operations.CELC
Q3 202413 Jan 2026